Sarms vs Peptides: 2024 Market Data, Brand Comparison, and Product Efficacy Analysis
Abstract: This 2024 analysis compares SARMs and peptides across market data, brand efficacy, and technical parameters. Peptides dominate the regenerative and anti-aging sector, with a 14.2% CAGR, while SARMs face regulatory headwinds. Key differentiators include peptide safety profiles (FDA-certified GMP facilities) vs. SARMs’ hepatotoxicity risks. Leading brands (e.g., Semaglutide, BPC-157) show superior bioavailability and targeted tissue repair. Logistics require cold-chain compliance for peptides; SARMs demand purity verification via third-party COAs. Market trends favor peptide-based therapeutics over SARMs for clinical applications, driven by patent expirations and expanded indications. Selection criteria prioritize certificate of analysis (CoA), manufacturing origin, and stability data.